Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The Gut Microbiome and Cancer Immunotherapy: Can We Use the Gut Microbiome as a Predictive Biomarker for Clinical Response in Cancer Immunotherapy?
Byeongsang Oh, Frances Boyle, Nick Pavlakis, et al.
Cancers (2021) Vol. 13, Iss. 19, pp. 4824-4824
Open Access | Times Cited: 46

Showing 1-25 of 46 citing articles:

Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial
Tina Cascone, Gozde Kar, Jonathan Spicer, et al.
Cancer Discovery (2023) Vol. 13, Iss. 11, pp. 2394-2411
Open Access | Times Cited: 59
Role of the Microbiota in Lung Cancer: Insights on Prevention and Treatment
Federica Pizzo, Zaira Maroccia, Ivano Hammarberg Ferri, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 11, pp. 6138-6138
Open Access | Times Cited: 32
The Role of the Gut Microbiome in Cancer Immunotherapy: Current Knowledge and Future Directions
Despoina Eugenia Kiousi, Antonia Z. Kouroutzidou, Konstantinos Neanidis, et al.
Cancers (2023) Vol. 15, Iss. 7, pp. 2101-2101
Open Access | Times Cited: 21
Immune checkpoint inhibitor-induced diarrhea and colitis: an overview
Marianne Zoghbi, Kathryn J Burk, Elio Haroun, et al.
Supportive Care in Cancer (2024) Vol. 32, Iss. 10
Open Access | Times Cited: 6
Bile acids, gut microbiota, and therapeutic insights in hepatocellular carcinoma
Yang Song, Harry Cheuk-Hay Lau, Xiang Zhang, et al.
Cancer Biology and Medicine (2023), pp. 1-19
Open Access | Times Cited: 16
The role of glycans in health and disease: Regulators of the interaction between gut microbiota and host immune system
Lucy I. Crouch, Cláudia S. Rodrigues, Cassie R. Bakshani, et al.
Seminars in Immunology (2024) Vol. 73, pp. 101891-101891
Open Access | Times Cited: 5
Global research trends on the links between gut microbiota and cancer immunotherapy: A bibliometric analysis (2012-2021)
Shanshan Yang, Suya Zhao, Yixiang Ye, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 21
HCC and Immunotherapy: The Potential Predictive Role of Gut Microbiota and Future Therapeutic Strategies
Carmelo Laface, E Lauricella, Girolamo Ranieri, et al.
Onco (2025) Vol. 5, Iss. 1, pp. 9-9
Open Access
Prioritizing gut microbial SNPs linked to immunotherapy outcomes in NSCLC patients by integrative bioinformatics analysis
Muhammad Faheem Raziq, N. A. Khan, Haseeb Manzoor, et al.
Journal of Translational Medicine (2025) Vol. 23, Iss. 1
Open Access
Immune checkpoint inhibitors: From friend to foe
Prem Rajak
Toxicology Reports (2025), pp. 102033-102033
Open Access
Potential predictive role of gut microbiota to immunotherapy in HCC patients: a brief review
Paola Muscolino, Barbara Granata, Fausto Omero, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 10
Integrative Oncology Approaches to Supporting Immune Checkpoint Inhibitor Treatment of Solid Tumours
Nina Fuller-Shavel, Jonathan Krell
Current Oncology Reports (2024) Vol. 26, Iss. 2, pp. 164-174
Open Access | Times Cited: 3
Attempting to Identify Bacterial Allies in Immunotherapy of NSCLC Patients
Anna Grenda, Ewelina Iwan, Paweł Krawczyk, et al.
Cancers (2022) Vol. 14, Iss. 24, pp. 6250-6250
Open Access | Times Cited: 16
Advances in efficacy prediction and monitoring of neoadjuvant immunotherapy for non-small cell lung cancer
Yunzhen Wang, Sha Huang, Xiangwei Feng, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 8
Effect of microbiome group on immune checkpoint inhibitors in treatment of gastrointestinal tumors.
Beibei Pei, Xiaoyan Ma, Na Wu, et al.
PubMed (2023) Vol. 35, Iss. 3, pp. 252-265
Closed Access | Times Cited: 7
Microbiota: A key factor affecting and regulating the efficacy of immunotherapy
Yao Jiang, Dingjiacheng Jia, Yong Sun, et al.
Clinical and Translational Medicine (2023) Vol. 13, Iss. 12
Open Access | Times Cited: 7
The role of gut microbiome in immune modulation in metastatic renal cell carcinoma
Jasna Deluce, Saman Maleki Vareki, Ricardo Fernandes
Therapeutic Advances in Medical Oncology (2022) Vol. 14
Open Access | Times Cited: 12
Gut and local microbiota in patients with cancer: increasing evidence and potential clinical applications
Anna Amela Valsecchi, Giorgia Ferrari, Chiara Paratore, et al.
Critical Reviews in Oncology/Hematology (2024) Vol. 197, pp. 104328-104328
Closed Access | Times Cited: 2
Implications of intestinal microecology and immune function alterations for immunotherapy outcomes in advanced unresectable lung adenocarcinoma
Shuang He, Tian Jin, Jianhua Zang, et al.
The Clinical Respiratory Journal (2024) Vol. 18, Iss. 5
Open Access | Times Cited: 2
Prognostic Impact of the Administration of Antibiotics and Proton Pump Inhibitors in Immune Checkpoint Inhibitor Combination Therapy for Advanced Renal Cell Carcinoma
Nanaka Katsurayama, Hiroki Ishihara, Ryo Ishiyama, et al.
Cancer Diagnosis & Prognosis (2024) Vol. 4, Iss. 4, pp. 496-502
Open Access | Times Cited: 2
Gut resistome of NSCLC patients treated with immunotherapy
Ewelina Iwan, Anna Grenda, Arkadiusz Bomba, et al.
Frontiers in Genetics (2024) Vol. 15
Open Access | Times Cited: 2
Analysis of Gut Microbiota Signature and Microbe-Disease Progression Associations in Locally Advanced Non-Small Cell Lung Cancer Patients Treated With Concurrent Chemoradiotherapy
Xi Yu, FangJie Liu, Bo Qiu, et al.
Frontiers in Cellular and Infection Microbiology (2022) Vol. 12
Open Access | Times Cited: 9
The negative effect of antibiotics on RCC patients with immunotherapy: A systematic review and meta-analysis
Zhiqiang Luo, Siyuan Hao, Yuxuan Li, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 9
Assessing the role of colonic and other anatomical sites uptake by [18F]FDG‐PET/CT and immune‐inflammatory peripheral blood indexes in patients with advanced non‐small cell lung cancer treated with first‐line immune checkpoint inhibitors
Alessio Rizzo, Ornella Cantale, Andrea Mogavero, et al.
Thoracic Cancer (2023) Vol. 14, Iss. 24, pp. 2473-2483
Open Access | Times Cited: 5
A Concerted Vision to Advance the Knowledge of Diabetes Mellitus Related to Immune Checkpoint Inhibitors
Maria V. Deligiorgi, Dimitrios T. Trafalis
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 8, pp. 7630-7630
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top